Neurogene (NASDAQ:NGNE) Earns Buy Rating from HC Wainwright

Neurogene (NASDAQ:NGNE)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $70.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 272.34% from the stock’s previous close.

NGNE has been the subject of a number of other reports. Wall Street Zen downgraded shares of Neurogene from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Neurogene in a research report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $42.50.

Neurogene Stock Up 10.9%

NASDAQ NGNE opened at $18.80 on Tuesday. The company has a 50-day simple moving average of $21.12 and a two-hundred day simple moving average of $22.09. Neurogene has a 12-month low of $6.88 and a 12-month high of $37.27. The firm has a market cap of $291.21 million, a price-to-earnings ratio of -4.57 and a beta of 1.60.

Neurogene (NASDAQ:NGNE) last released its earnings results on Thursday, November 13th. The company reported ($0.99) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.27. Equities analysts expect that Neurogene will post -4.27 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets lifted its position in shares of Neurogene by 89.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock valued at $36,000 after buying an additional 978 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in shares of Neurogene by 43.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company’s stock valued at $61,000 after purchasing an additional 1,232 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Neurogene by 17.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock valued at $82,000 after purchasing an additional 1,059 shares during the last quarter. Bridgeway Capital Management LLC bought a new position in shares of Neurogene during the 3rd quarter valued at approximately $187,000. Finally, Brevan Howard Capital Management LP purchased a new stake in Neurogene during the 3rd quarter valued at $223,000. Institutional investors own 52.37% of the company’s stock.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.